Muvon Therapeutics Revenue and Competitors

MUVON Therapeutics is a Swiss biotechnology start-up with the goal of developing and commercializing an autologous cell therapy for the regeneration of skeletal muscle tissue, focusing initially on the treatment of stress urinary incontinence. Compared to existing treatment options which have drawbacks ranging from low and short term efficacy (for conservative treatments) to potentially serious adverse events (for more potent surgical approaches), our novel regenerative approach will provide a safe and effective treatment to millions of people suffering from this highly prevalent and under-diagnosed condition, allowing them to live to their full personal and professional potential. Following 12 years of preclinical research at the University of Zurich, our team received the approval for a first in-man trial in 2015 and completed the GMP validation of our proprietary production process at the facilities of the Wyss Zurich, leading to the start of the phase I clinical trial at the University Hospital of Zurich in January 2020. The first patient was treated with the MPC Therapy in March 2020.